Preimplantation Genetic Testing Market Scenario
The preimplantation genetic testing market is grow USD 0.65 Billion in 2032 and is projected to register a CAGR of around 10.2% over the forecast period 2023-2032.
Preimplantation genetic testing is a wide term, which is used to describe the genetic analysis of cells of an embryo, and the outcome is used for analysis and guide, which embryos should transfer to the uterus.
Also, nowadays, preimplantation genetic testing has become much more common in North America and Europe due to innovation in genetic technology like NGS and FISH over the traditional genetic technology
Population suffering from disorders related to the gene is expected to drive the preimplantation genetic testing market. Thus, awareness of people about genetic disorders helps to avoid the risk of having babies with certain genetic disorders.
March of Dimes, a voluntary health group of the US stated about 60%,34% and 6% of babies with serious birth defects were born in developing countries, middle-income countries and rich countries respectively.
Additionally,3.3 million children less than five years die each year from serious birth defects worldwide. But genetic medical services and effective interventions, especially in developing countries, could reduce disability and mortality by up to 70%.
Hence raising awareness of preimplantation genetic testing drive the global preimplantation genetic testing market.
Early diagnosis of chromosomal disorders lowers the likelihood that children would be born with inherited chromosomal abnormalities, potentially reducing the number of children with congenital illnesses. Due to the rise in demand for PGT services in recent years, this has occurred. Additionally, it is projected that the market for genomic diagnostics would have increased demand due to the rising prevalence of numerous gene-related ailments.
It is also anticipated that preimplantation genetic diagnosis (PGD), which is already advised for couples undergoing IVF therapy due to infertility and advanced maternal age, will experience significant demand, which will in turn have a positive impact on the market's growth. Preimplantation genetic testing demand is also anticipated to rise as a result of positive market participant and service provider actions to promote IVF treatments.
July 2023:Thermo Fisher Scientific introduced two brand-new PGT-A research tools based on next-generation sequencing. For intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF), this kind of testing is employed. The Ion Torrent Genexus Integrated Sequencer's initial research-use reproductive health tests are the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit. This rollout gives additional research laboratories access to next-generation sequencing's advantages and offers the possibility of quick internal testing and analysis.
The global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.
The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS). By type, it is divided into chromosomal abnormalities, X-linked diseases, embryo testing, aneuploidy screening, LA typing, and others. By Application it is segmented into embryo HLA typing for stem cell therapy prognosis, late-onset genetic disorders, inherited the genetic disease and others. By technology, the market is divided into
next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, and single-nucleotide polymorphism. By product and service, it is divided into reagents and consumables, instruments and software and services and lastly by end user the market is divided into maternity centers & fertility clinics, hospitals, diagnostic labs and research laboratories & academic institutes
Preimplantation genetic diagnosis (PGD) segment is expected to hold the largest market share of the preimplantation genetic testing market owing to rising awareness patients as well as healthcare professionals about genetic testing. Also, preimplantation genetic screening (PGS) segment is anticipated profitable growth during the forecast period as it reduces the miscarriage risk, increase the possibility of a healthy pregnancy in all age groups
By technology, the next-generation sequencing segment also expected to hold a large share as its cost is reduced and its capability to detect mosaicism.
By product & service, the reagents and consumables segment expected to hold the largest market share as there is continuous declination infertility of female due to the increase in maternity age.
In the current scope of the study, the segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The preimplantation genetic testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Preimplantation Genetic Testing market in the Middle East and Africa has been segmented into the Middle East and Africa.
- Natera, Inc.
- CooperSurgical, Inc.
- Hoffmann-La Roche AG
- Illumina, Inc.
- Reprogenetics, LLC
- Genea Limited
- PerkinElmer, Inc.
- Genesis Genetics Ltd.
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific, Inc
- Bioarrayn Genetics
- Laboratory Corporation of America Holdings
- California Pacific Medical Center
- Reproductive Health Science Ltd
October 2022:To improve its preimplantation genetic testing (PGT) capabilities, Cooper Genomics has licensed BioSkryb Genomics' patented ResolveDNA genomic amplification technology. Cooper will be able to sell and distribute BioSkryb technology for the PGT and women's reproductive health markets internationally due to the deal. ResolveDNA single-cell genomic amplification technology from BioSkryb, which combines unique Primary Template-directed Amplification (PTA) technology, will be made available to Cooper as a result of the agreement. Gaining access to the BioSkryb technology would boost Cooper Genomics' beneficial effects on the field of women's reproductive health and on the lives of patients everywhere by enabling a new level of genetic analysis and testing accuracy.
Regional Market Summary
March of Dimes, the US voluntary health group stated that 7.9 million children are born with a serious birth defect of genetic or partially genetic origin, that is, 6% of total births in a year worldwide. This estimation is drawn from a study of 193 countries. As the genetic defects are growing, there is an increase in awareness about preimplantation genetic testing in population worldwide.
US Department of Health & Human Services stated that Infertility is very common. Thus, out of 100 couples in the US, about 12 to 13 of them have trouble getting pregnant. About 10 in 100 (6.1 million) women in the US aged 15 to 44 have a problem in getting pregnant or staying pregnant. Hence the prevalence of infertility causes an increase in the number of IVF procedures in the US, which is expected to drive the market.
As the maternal age in Europe is increasing complications regarding childbirth along with the threat of abnormalities in chromosomes is also rising. This leads to an increase in preimplantation genetic testing for baby birth with normal genes.
The rising participation of market players is also strongly impacting the growth of the Asia-Pacific Preimplantation Genetic Testing market.
On the other hand, the Middle East and Africa held the least share in the global market due to the low economic development, especially within the African region.
Preimplantation Genetic Testing Market Segmentation
Preimplantation Genetic Testing by Procedure Outlook
- Preimplantation Genetic Diagnosis (PGD)
- Preimplantation Genetic Screening (PGS) Beta Thalassemia
Preimplantation Genetic Testing by Type Outlook
- Chromosomal Abnormalities
- X-linked Diseases
- Embryo Testing
- Aneuploidy Screening
- HLA Typing
Preimplantation Genetic Testing by Application outlook
- Embryo HLA typing for stem cell therapy
- IVF Prognosis
- Late-Onset Genetic Disorders
- Inherited Genetic Disease
Preimplantation Genetic Testing by Technology Outlook
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Fluorescence in Situ Hybridization
- Comparative Genomic Hybridization
- Single-Nucleotide Polymorphism
Preimplantation Genetic Testing by Product and Service Outlook
- Reagents and Consumables
- Software and Services
Global Preimplantation Genetic Testing by End User outlook
- Maternity Centers & Fertility Clinics
- Hospitals, Diagnostic Labs
- Research Laboratories & Academic Institutes
Global Preimplantation Genetic Testing by Region Outlook
- North America
- Latin America
- Western Europe
- Rest of Western Europe
- Eastern Europe
- South Korea
- Rest of Asia-Pacific
- Pharmaceutical companies
- Government and private laboratories
- Research and development (R&D) companies
- Research laboratories
- Market research and consulting service providers
USD 0.65 Billion
Value (USD Million)
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Procedure, Type, Application, Technology, Product and Service
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science Ltd
Key Market Opportunities
New product launches and R&D Amongst major key Players
Key Market Drivers
Rising awareness regarding its benefits
Preimplantation Genetic Testing Market Highlights:
Frequently Asked Questions (FAQ) :
The preimplantation genetic testing market would register a CAGR of 10.2% during the forecast period.
The preimplantation genetic testing market valuation in 2032 USD 0.65 Billion.
Rising awareness regarding its benefits would increase the preimplantation genetic testing market volume.
The Preimplantation genetic diagnosis (PGD) segment would lead to the preimplantation genetic testing market.
The next-generation sequencing has the upper hand in the preimplantation genetic testing market.
Key Questions Answered
Request Free Sample
- ✅Global Market Outlook
- ✅In-depth analysis of global and regional trends
- ✅Analyze and identify the major players in the market, their market share, key developments, etc.
- ✅To understand the capability of the major players based on products offered, financials, and strategies.
- ✅Identify disrupting products, companies, and trends.
- ✅To identify opportunities in the market.
- ✅Analyze the key challenges in the market.
- ✅Analyze the regional penetration of players, products, and services in the market.
- ✅Comparison of major players’ financial performance.
- ✅Evaluate strategies adopted by major players.
Why Choose Market Research Future?
Speak to Analyst
- ✅Vigorous research methodologies for specific market.
- ✅Knowledge partners across the globe
- ✅Large network of partner consultants.
- ✅Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- ✅Trusted by fortune 500 companies/startups/universities/organizations
- ✅Large database of 5000+ markets reports.
- ✅Effective and prompt pre- and post-sales support.